These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22934796)

  • 21. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
    Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT
    Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
    Chen JH; Wu PN; Huang SC; Hsu PJ; Hsu JC
    Curr Med Res Opin; 2021 Feb; 37(2):245-252. PubMed ID: 33251875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [On the brink of a new era in the treatment of chronic hepatitis C virus infection in Denmark].
    Eiset AH; Holm MP; Leutscher PD
    Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Pricing Evolution in Hepatitis C.
    Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
    PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of new oral hepatitis C antiviral drugs.
    Vispo E; Barreiro P; Soriano V
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):5-16. PubMed ID: 23094639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.
    Maughan A; Ogbuagu O
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):219-227. PubMed ID: 29271660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.
    Majumdar A; Kitson MT; Roberts SK
    Drugs; 2015 May; 75(8):823-34. PubMed ID: 25943281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic behaviour for a HCV+ patient].
    Buffet C
    Presse Med; 2004 Apr; 33(7):497-8. PubMed ID: 15105775
    [No Abstract]   [Full Text] [Related]  

  • 29. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
    Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vedroprevir in the management of hepatitis C virus infection.
    Abutaleb A; Kottilil S
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1399-1402. PubMed ID: 29053394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
    Höner zu Siederdissen C; Cornberg M
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2411-4. PubMed ID: 25390631
    [No Abstract]   [Full Text] [Related]  

  • 34. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.
    Due OT; Chaikledkaew U; Genuino AJM; Sobhonslidsuk A; Thakkinstian A
    Biomed Res Int; 2019; 2019():2301291. PubMed ID: 31815126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
    Nordien R; Sonderup MW; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of resistance in HCV treatment.
    Vermehren J; Sarrazin C
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):487-503. PubMed ID: 23199507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
    PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    Vermehren J; Park JS; Jacobson IM; Zeuzem S
    J Hepatol; 2018 Nov; 69(5):1178-1187. PubMed ID: 30006068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection.
    Néant N; Solas C
    Int J Antimicrob Agents; 2020 Jul; 56(1):105571. PubMed ID: 30394302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.